Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Biocept, OHSU Reach Deal on Liquid Biopsy

Biocept, OHSU Reach Deal on Liquid Biopsy

Apr 03, 2017
|
staff reporter

NEW YORK (GenomeWeb) – Biocept today announced a preferred provider collaboration and services agreement with Oregon Health & Sciences University granting the university the rights to offer Biocept's Target Selector liquid biopsy testing services throughout Oregon.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Preprints During Lockdown

New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.

ApoE and COVID-19

A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.

Search for Genetic Clues to COVID-19 Severity

Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.

PNAS Papers on Retinal Development, Adoptive T Cell Transfer, Blood Cell Differentiation

In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.

What's Popular?

In Business News

  1. Roche Acquires Sequencing Company Stratos Genomics

  2. NeoGenomics, Inivata Partner to Commercialize Lung Cancer Liquid Biopsy Test

  3. BioCore, SolGent, Seasun Get FDA Emergency Use Authorizations for Coronavirus Tests

  4. Genetic Technologies Prices $8M Public Offering

  5. Sysmex Partec to Distribute De Novo Flow Cytometry Software Worldwide

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.